On July 29, the National Medical Products Administration approved four innovative drugs at once, covering autoimmunity, metabolite,Anti-infectionand the four major fields of traditional Chinese medicine! 1.Huahai
· State Intellectual Property Office: China's Trademark Legislation Upgrades from "Partial Revision" to "Systematic Improvement" · Canada-China Patent Prosecution Highway (PPH) Pilot Project Extended · China-EU
From July 22 to 24, the Great Nation New Drug CPIC 2026 Global Conference was held at the National Exhibition and Convention Center in Shanghai. As
This week, the biopharmaceutical field saw several major advances: the Shengbai ® Gudao hearing aid was approved domestically; Wuwei Disinfection Drink Granules and Banxia Baizhu Gastrodia
This week, 10 medical innovation companies completed a new round of financing: among them, Diyingga Technology completed several hundred million yuan in Series C financing; Wuzhensong
· Tianjin Holds Special Training on Enterprise Intellectual Property Compliance Management System Construction and PCT Patent Application · State Intellectual Property Office Approves: FRAND Factors Should
Cell therapy is the third core track driving the iteration and upgrading of the biopharmaceutical industry, following small molecule chemical drugs and antibody drugs. Relying on
Introduction On July 21-22, the “Pharmaceutical BD Intellectual Property Due Diligence Practice Forum,” hosted by IP Link, was successfully held in Shanghai. Tang Huadong, partner at Merits
Introduction: In 2026, domestic pharmaceutical innovation will enter a critical period of accelerated iteration. Patent examination has become increasingly strict, major drugs are expiring in concentrated
This week, multiple findings were announced in biomedicine: aging research revealed that abnormal EP2 signaling in macrophages is the core trigger, and clearing senescent neutrophils can reverse
A Leading Chinese Intellectual Property Legal Service Provider
